| HLH | Hemophagocytic lymphohistiocytosis |
| CXCL | C-X-C motif chemokine ligand |
| NK | Natural killer |
| MAS | Macrophage activation syndrome |
| CAR | Chimeric antigen receptor |
| IFN | Interferon |
| CXCR | C-X-C motif chemokine receptor |
| AST | Aspartate aminotransferase |
| EULAR | European Alliance of Associations for Rheumatology |
| ACR | American College of Rheumatology |
| EBV | Epstein–Barr virus |
| IQR | Interquartile range |
| pg | Picogram |
| mL | Milliliter |
| CNS | Central nervous system |
| CSF | Cerebrospinal fluid |
| ONID | Other neuroinflammatory disorders |
| ng | Nanogram |
| AUC | Area under the curve |
| SEBVTCL | Systemic Epstein–Barr virus-positive T-cell lymphoma of childhood |
| CAEBV | Chronic active Epstein–Barr virus disease |
| TCR | T-cell receptor |
| WHO | World Health Organization |
| NACHO | North American Consortium for Histiocytosis |
| HR | Hazard ratio |
| CI | Confidence interval |
| RED | Ruxolitinib, emapalumab, dexamethasone |
| CRP | C-reactive protein |
| ELISA | Enzyme-linked immunosorbent assay |
| FDA | Food and Drug Administration |
| GVHD | Graft-versus-host disease |
| IEC-HS | Immune effector cell-associated HLH-like syndrome |
| CRS | Cytokine release syndrome |
| ICANS | Immune effector cell-associated neurotoxicity syndrome |
| ASTCT | American Society for Transplantation and Cellular Therapy |